International randomized trial on the effect of revascularization or optimal medical therapy of chronic total coronary occlusions with myocardial ischemia - ISCHEMIA-CTO trial – rationale and design
Study context
- Population
- Patients with a chronic total occlusions (CTO) lesion, target vessel diameter ≥ 2.5 mm and myocardial ischemia in the relevant territory, after ≥3 months of optimal medical therapy (OMT); Cohort A: low- or asymptomatic (QoL score > 60 and/or CCS class < 2) with >10 % left ventricle (LV) ischemia; Cohort B: symptomatic (QoL score < 60 or CCS class angina > 1) with ≥5% LV ischemia
- Planned comparison
- OMT and CTO-PCI vs OMT alone
Methodological detailsinternational, two cohorts by Seattle Questionnaire (SAQ) score, All patients first receive OMT for at least 3 months; non-CTO lesions managed per guidelines, Myocardial ischemia and QoL (SAQ) assessed before randomization
- International
- Two cohorts by SAQ score
- All patients first receive OMT for at least 3 months; non-CTO lesions managed per guidelines
- Myocardial ischemia and QoL (SAQ) assessed before randomization
No results yet. This paper sets out the design of a trial; its results are to come.
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
International randomized trial on the effect of revascularization or optimal medical therapy of chronic total coronary occlusions with myocardial ischemia - ISCHEMIA-CTO trial – rationale and design. Am Heart J. Published 21 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →